

**CENTER FOR DRUG EVALUATION AND  
RESEARCH**

*APPLICATION NUMBER:*  
**202343Orig1s000**

**PROPRIETARY NAME REVIEW(S)**

**Department of Health and Human Services  
Public Health Service  
Food and Drug Administration  
Center for Drug Evaluation and Research  
Office of Surveillance and Epidemiology  
Office of Medication Error Prevention and Risk Management**

**Proprietary Name Review**

Date: September 26, 2011

Reviewer(s): Anne Tobenkin, PharmD  
Division of Medication Error Prevention and Analysis

Team Leader Lubna Merchant, PharmD, M.S.  
Division of Medication Error Prevention and Analysis

Division Director Carol Holquist, RPh.  
Division of Medication Error Prevention and Analysis

Drug Name(s): Juvisync (Sitagliptin and Simvastatin) Tablets

Strengths: 100 mg/10 mg, 100 mg/20 mg, 100 mg/40 mg

Application Type/Number: NDA 202343

Applicant/sponsor: Merck

OSE RCM #: 2011-3271

\*\*\* This document contains proprietary and confidential information that should not be released to the public.\*\*\*

## CONTENTS

1	INTRODUCTION.....	1
1.1	Regulatory History.....	1
1.2	Product Information.....	1
2	RESULTS.....	1
2.1	Promotional Assessment.....	1
2.2	Safety Assessment.....	1
3	CONCLUSIONS.....	3
3.1	Comments to the Applicant.....	3
4	REFERENCES.....	4
	APPENDICES.....	6

## 1 INTRODUCTION

This review evaluates the proposed proprietary name, Juvisync, from a safety and promotional perspective. The sources and methods used to evaluate the proposed name are outlined in the reference section and Appendix A respectively.

### 1.1 REGULATORY HISTORY

The Applicant, Merck, submitted the proprietary name request for Juvisync Tablets on September 2, 2011. The Applicant had submitted two names previously, (b) (4) which was found unacceptable in OSE review # 2011-2427 and (b) (4) which was withdrawn by the Applicant on September 2, 2011.

Additionally, a label and labeling review (OSE review # 2011-300) was also completed on June 20, 2011. The label and labeling recommendations were sent to the Applicant.

### 1.2 PRODUCT INFORMATION

Juvisync is a combination product which contains Sitagliptin and Simvastatin. Juvisync is indicated for glycemic control in the setting of Type 1 diabetes and to decrease cholesterol. The proposed strengths of Juvisync include; 100 mg/10 mg, 100 mg/20 mg, and 100 mg/40 mg tablets. The recommended dose and frequency of Juvisync is one tablet by mouth once daily. Juvisync will be available in physician samples and bottles of 30, 90 and 1000 tablets and can be stored at room temperature.

## 2 RESULTS

The following sections provide the information obtained and considered in the evaluation of the proposed proprietary name.

### 2.1 PROMOTIONAL ASSESSMENT

DDMAC determined the proposed name is acceptable from a promotional perspective. DMEPA and the Division of Metabolic and Endocrinology Products concurred with the findings of DDMAC's promotional assessment of the proposed name.

### 2.2 SAFETY ASSESSMENT

The following aspects of the name were considered in the overall evaluation.

#### 2.2.1 *United States Adopted Names (USAN) SEARCH*

The September 9, 2011 United States Adopted Name (USAN) stem search identified that a USAN stem is not present in the proposed proprietary name.

#### 2.2.2 *Components of the Proposed Proprietary Name*

Per the Applicant and DMEPA's evaluation of the proprietary name, Juvisync, is a coined term that has no intrinsic meaning. This proprietary name is comprised of a single word that does not contain any components (i.e. a modifier, route of administration, dosage form, etc) that can contribute to medication error or render the name unacceptable.

### 2.2.3 FDA Name Simulation Studies

Twenty nine practitioners participated in DMEPA's prescription studies. The most common misinterpretation in the written study was with the first letter 'J' for 'T' and 'L'. The most common misinterpretations in the voice study was confusion with vowels 'i' for 'a', 'e', and 'o' and 'y' for 'i'. See Appendix C for the complete listing of interpretations from the verbal and written prescription studies.

### 2.2.4 Comments from Other Review Disciplines

In response to the OSE, September 14, 2011 e-mail, the Division of Metabolic and Endocrinology Products (DMEP) did not forward any comments or concerns relating to the proposed name at the initial phase of the name review.

### 2.2.5 Failure Mode and Effects Analysis of Similar Names

Appendix B lists possible orthographic and phonetic misinterpretations of the letters appearing in the proposed name, Juvisync. Table 1 lists the names with orthographic, phonetic, or spelling similarity to the proposed proprietary name, Juvisync identified by the primary reviewer (PR), the Expert Panel Discussion (EPD), other review disciplines.

**Table 1: Collective List of Potentially Similar Names (DMEPA, EPD and Other Disciplines)**

Look Similar		Sound Similar		Look and Sound Similar	
Name	Source	Name	Source	Name	Source
Jenloga	EPD	Nuvaring	EPD	Juvisync	EPD
Tasigna	EPD	Jantoven	EPD	Januvia	EPD
Tikosyn	EPD			(b) (4)	EPD
Tussigon	EPD				
(b) (4)	EPD				
(b) (4)	EPD				
Invega	EPD				
Invagesic	EPD				
Visudyne	EPD				
Jevantique	EPD				
Junovan	EPD				
Junifer	EPD				
Enjuvia	EPD				
(b) (4)	PR				
(b) (4)	PR				

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.